company background image
ANIK

Anika Therapeutics NasdaqGS:ANIK Stock Report

Last Price

US$22.51

Market Cap

US$327.4m

7D

-0.3%

1Y

-48.0%

Updated

29 Jun, 2022

Data

Company Financials +
ANIK fundamental analysis
Snowflake Score
Valuation2/6
Future Growth3/6
Past Performance0/6
Financial Health6/6
Dividends0/6

ANIK Stock Overview

Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies in the United States, Europe, and internationally.

Rewards

Earnings are forecast to grow 109.3% per year

Risk Analysis

No risks detected for ANIK from our risk checks.

Anika Therapeutics Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Anika Therapeutics
Historical stock prices
Current Share PriceUS$22.51
52 Week HighUS$45.81
52 Week LowUS$19.95
Beta1.11
1 Month Change2.09%
3 Month Change-10.35%
1 Year Change-48.00%
3 Year Change-45.68%
5 Year Change-54.82%
Change since IPO543.14%

Recent News & Updates

Shareholder Returns

ANIKUS BiotechsUS Market
7D-0.3%3.8%1.6%
1Y-48.0%-25.8%-20.8%

Return vs Industry: ANIK underperformed the US Biotechs industry which returned -26.1% over the past year.

Return vs Market: ANIK underperformed the US Market which returned -20.4% over the past year.

Price Volatility

Is ANIK's price volatile compared to industry and market?
ANIK volatility
ANIK Average Weekly Movement6.0%
Biotechs Industry Average Movement13.1%
Market Average Movement8.1%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market3.2%

Stable Share Price: ANIK is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: ANIK's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1983297Cheryl Blanchardhttps://www.anikatherapeutics.com

Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management product family consists of Monovisc, Orthovisc, Cingal, and Hyvisc that are indicated to provide pain relief from osteoarthritis conditions; and joint preservation and restoration product family comprise a portfolio of approximately 150 bone preserving joint technology products, a line of sports medicine soft tissue repair solutions, and orthopedic regenerative solutions products.

Anika Therapeutics Fundamentals Summary

How do Anika Therapeutics's earnings and revenue compare to its market cap?
ANIK fundamental statistics
Market CapUS$327.38m
Earnings (TTM)-US$1.64m
Revenue (TTM)US$150.20m

2.2x

P/S Ratio

-200.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ANIK income statement (TTM)
RevenueUS$150.20m
Cost of RevenueUS$60.09m
Gross ProfitUS$90.11m
Other ExpensesUS$91.74m
Earnings-US$1.64m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.11
Gross Margin59.99%
Net Profit Margin-1.09%
Debt/Equity Ratio0%

How did ANIK perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is ANIK undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • PEG Ratio

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ANIK?

Other financial metrics that can be useful for relative valuation.

ANIK key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue1.7x
Enterprise Value/EBITDA89.2x
PEG Ration/a

Price to Sales Ratio vs Peers

How does ANIK's PS Ratio compare to its peers?

ANIK PS Ratio vs Peers
The above table shows the PS ratio for ANIK vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average1801x
AFMD Affimed
10.5x43.0%US$419.5m
GRNA GreenLight Biosciences Holdings
182.4xn/aUS$278.4m
GRCL Gracell Biotechnologies
6762.7x90.3%US$369.1m
HUMA Humacyte
248.3x67.2%US$332.7m
ANIK Anika Therapeutics
2.2x7.9%US$327.4m

Price-To-Sales vs Peers: ANIK is good value based on its Price-To-Sales Ratio (2.2x) compared to the peer average (1801x).


Price to Earnings Ratio vs Industry

How does ANIK's PE Ratio compare vs other companies in the US Biotechs Industry?

Price-To-Sales vs Industry: ANIK is good value based on its Price-To-Sales Ratio (2.2x) compared to the US Biotechs industry average (13.4x)


Price to Sales Ratio vs Fair Ratio

What is ANIK's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ANIK PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio2.2x
Fair PS Ratio2.1x

Price-To-Sales vs Fair Ratio: ANIK is expensive based on its Price-To-Sales Ratio (2.2x) compared to the estimated Fair Price-To-Sales Ratio (2.1x).


Share Price vs Fair Value

What is the Fair Price of ANIK when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: ANIK ($22.51) is trading above our estimate of fair value ($5.36)

Significantly Below Fair Value: ANIK is trading above our estimate of fair value.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ANIK's PEG Ratio to determine if it is good value.


Discover undervalued companies

Future Growth

How is Anika Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

Future Growth Score

3/6

Future Growth Score 3/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


109.3%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ANIK is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.9%).

Earnings vs Market: ANIK is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: ANIK is expected to become profitable in the next 3 years.

Revenue vs Market: ANIK's revenue (7.9% per year) is forecast to grow slower than the US market (8.3% per year).

High Growth Revenue: ANIK's revenue (7.9% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if ANIK's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Past Performance

How has Anika Therapeutics performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-45.0%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: ANIK is currently unprofitable.

Growing Profit Margin: ANIK is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: ANIK is unprofitable, and losses have increased over the past 5 years at a rate of 45% per year.

Accelerating Growth: Unable to compare ANIK's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ANIK is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (96.9%).


Return on Equity

High ROE: ANIK has a negative Return on Equity (-0.57%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is Anika Therapeutics's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: ANIK's short term assets ($165.3M) exceed its short term liabilities ($27.0M).

Long Term Liabilities: ANIK's short term assets ($165.3M) exceed its long term liabilities ($29.5M).


Debt to Equity History and Analysis

Debt Level: ANIK is debt free.

Reducing Debt: ANIK had no debt 5 years ago.

Debt Coverage: ANIK has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: ANIK has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Discover healthy companies

Dividend

What is Anika Therapeutics's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate ANIK's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ANIK's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ANIK's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ANIK's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as ANIK has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

2.1yrs

Average management tenure


CEO

Cheryl Blanchard (57 yo)

2.33yrs

Tenure

US$4,202,608

Compensation

Dr. Cheryl Renee Blanchard, Ph.D. serves as the President & Chief Executive Officer of Anika Therapeutics, Inc. since April 26, 2020. She serves as Director of Vigil Neuroscience, Inc. Since November 2020....


CEO Compensation Analysis

Compensation vs Market: Cheryl's total compensation ($USD4.20M) is above average for companies of similar size in the US market ($USD2.81M).

Compensation vs Earnings: Cheryl's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: ANIK's management team is considered experienced (2.1 years average tenure).


Board Members

Experienced Board: ANIK's board of directors are considered experienced (3.7 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: ANIK insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Anika Therapeutics, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Anika Therapeutics, Inc.
  • Ticker: ANIK
  • Exchange: NasdaqGS
  • Founded: 1983
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$327.382m
  • Shares outstanding: 14.54m
  • Website: https://www.anikatherapeutics.com

Number of Employees


Location

  • Anika Therapeutics, Inc.
  • 32 Wiggins Avenue
  • Bedford
  • Massachusetts
  • 1730
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/06/29 00:00
End of Day Share Price2022/06/29 00:00
Earnings2022/03/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.